Integrated mRNA Workflows: From DNA Template to Drug Product

• Bring DNA template, IVT, RNA drug substance, LNP formulation and drug product into one connected workflow  
• Improve RNA quality early through aligned template design, IVT and data-driven optimization  
• Reduce delays and rework by keeping processes consistent as program scale  
• Move more smoothly from research grade to cGMP with fewer resets along the way  
• Work with one partner who stays close to your program as it progresses 

Aldevron supports mRNA developers with a connected approach that brings together DNA templates, IVT, RNA production, and downstream delivery into one workflow. 

Rather than treating each step separately, the focus is on how these pieces work together. That starts upstream, with the right template strategy—whether you are using plasmid-based or cell-free options like Alchemy™ Cell-Free DNA—and continues through IVT, where Codex® HiCap RNA Polymerase-enabled processes improve mRNA quality and consistency early on. IVT screening then helps optimize conditions before programs need to scale, reducing the need for rework later. 

As programs move forward, this becomes even more important. Keeping materials, processes and knowledge aligned makes it easier to carry decisions from research into cGMP manufacturing without having to go back and fix things. 

The result is a more predictable path through development—with fewer handoffs, better RNA quality, and less disruption as programs move towards clinical production.

One partner. Fewer handoffs. 

Working with a single partner simplifies your mRNA workflow and reduces the friction that comes with multiple vendors. 

From DNA template through RNA drug substance, LNP formulation and drug product, Aldevron helps streamline development and manage risk at each transition. 

Designed to improve outcomes at every step 

Upstream design, IVT performance and downstream processing are aligned from the start. 

This helps protect RNA integrity, reduce variability, and deliver more consistent performance as programmes progress. 

Scalable from development to manufacturing 

Phase-appropriate support allows you to move from early work into clinical manufacturing without unnecessary rework. 

Processes are designed with scale in mind, helping teams' transition more predictably as requirements evolve. 

Connected expertise across the mRNA workflow 

DNA, RNA drug substance, LNP formulation and drug product are supported by teams who work across the full workflow. 

That alignment helps avoid disconnects, reduces delays, and keeps development moving. 

Move forward with confidence 

Aldevron’s quality systems and regulatory experience are designed to support progression towards clinical manufacturing. 

With a clear path from development through to cGMP, teams can move forward with greater control and fewer unknowns.